180 related articles for article (PubMed ID: 31171817)
21. IBTK Haploinsufficiency Affects the Tumor Microenvironment of Myc-Driven Lymphoma in E-myc Mice.
Vecchio E; Fiume G; Mignogna C; Iaccino E; Mimmi S; Maisano D; Trapasso F; Quinto I
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019112
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.
Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K
Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092
[TBL] [Abstract][Full Text] [Related]
23. PLK1: a promising and previously unexplored target in double-hit lymphoma.
Hassan QN; Alinari L; Byrd JC
J Clin Invest; 2018 Dec; 128(12):5206-5208. PubMed ID: 30395539
[TBL] [Abstract][Full Text] [Related]
24. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.
Ott G; Rosenwald A; Campo E
Blood; 2013 Dec; 122(24):3884-91. PubMed ID: 24009228
[TBL] [Abstract][Full Text] [Related]
25. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
Park SI; Lin CP; Ren N; Angus SP; Dittmer DP; Foote M; Parton T; Bhatt AP; Fedoriw YD; Roth DP; Cann ML; Johnson GL; Damania B
Target Oncol; 2019 Oct; 14(5):563-575. PubMed ID: 31429028
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth.
Kendrick S; Muranyi A; Gokhale V; Hurley LH; Rimsza LM
J Med Chem; 2017 Aug; 60(15):6587-6597. PubMed ID: 28605593
[TBL] [Abstract][Full Text] [Related]
28. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
29. "Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.
Eldessouki T; Hanley K; Hamadeh F; Oshilaja OO; Sturgis CD
Diagn Cytopathol; 2018 Sep; 46(9):807-811. PubMed ID: 30043475
[TBL] [Abstract][Full Text] [Related]
30. Novel oncogene 5MP1 reprograms c-Myc translation initiation to drive malignant phenotypes in colorectal cancer.
Sato K; Masuda T; Hu Q; Tobo T; Gillaspie S; Niida A; Thornton M; Kuroda Y; Eguchi H; Nakagawa T; Asano K; Mimori K
EBioMedicine; 2019 Jun; 44():387-402. PubMed ID: 31175057
[TBL] [Abstract][Full Text] [Related]
31. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
[TBL] [Abstract][Full Text] [Related]
32. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
[TBL] [Abstract][Full Text] [Related]
33. High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.
Zhang J; Weng Z; Huang Y; Li M; Wang F; Wang Y; Rao H
Am J Surg Pathol; 2020 Dec; 44(12):1602-1611. PubMed ID: 32991338
[TBL] [Abstract][Full Text] [Related]
34. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
35. The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell Lymphoma.
Wong DM; Li L; Jurado S; King A; Bamford R; Wall M; Walia MK; Kelly GL; Walkley CR; Tarlinton DM; Strasser A; Heierhorst J
Cell Rep; 2016 Feb; 14(6):1488-1499. PubMed ID: 26832406
[TBL] [Abstract][Full Text] [Related]
36. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
Wang W; Hu S; Lu X; Young KH; Medeiros LJ
Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
[TBL] [Abstract][Full Text] [Related]
37. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
[TBL] [Abstract][Full Text] [Related]
38. Cytomorphologic findings of B-cell lymphomas with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas).
da Cunha Santos G; Ko HM; Saieg MA; Boerner SL; Lai SW; Bailey D; Geddie WR
Cancer Cytopathol; 2011 Aug; 119(4):254-62. PubMed ID: 21560251
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
40. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
Ren Y; Bi C; Zhao X; Lwin T; Wang C; Yuan J; Silva AS; Shah BD; Fang B; Li T; Koomen JM; Jiang H; Chavez JC; Pham LV; Sudalagunta PR; Wan L; Wang X; Dalton WS; Moscinski LC; Shain KH; Vose J; Cleveland JL; Sotomayor EM; Fu K; Tao J
J Clin Invest; 2018 Dec; 128(12):5517-5530. PubMed ID: 30260324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
